Following a reassessment of further evidence pertaining to the safety, effectiveness and costeffectiveness of brachytherapy for the treatment of prostate cancer, interim public funding should continue for patients with prostate cancer meeting the following criteria:
- at clinical stages T1 and T2 with Gleason scores of less than or equal to 6, prostate specific antigen (PSA) of less than or equal to 10 ng/ml, gland volume less than 40 cc and with life expectancy of more than 10 years; and
- where the treatment is conducted at approved sites.